In businesses, big or small, ranging from manufacturing to music, the fight for intellectual property is getting intense. Neglect it and you could be out of business.

BT asks the who’s who of India’s corporate world—as well as some professionals and leaders from other fields for good measure—to jog their memory and recall the best advice they ever got. What the advice was, who gave it to them and when, and how it helped them.

The promoters of Zandu Pharma and Fem Care Pharma recently sold their stakes at attractive valuations. All the deals were struck above the prevailing stock prices of the two companies, an enviable feat considering the depressed economic and market conditions.

Will Emami’s acquisition of Zandu Pharma change the landscape of the consumer products sector?

After years of rollicking appreciation, companies that make up the BT 500 are going through one of their toughest phases in a long, long time. As stocks get mercilessly hammered, this may just be the time when the men are separated from the boys. Virendra Verma reports.

Ranbaxy gets on the wrong side of regulatory bodies.

Analytics empower organisations to stay one step ahead, to out-think and out-execute the competition.

After Daiichi Sankyo’s purchase of Ranbaxy Labs, Teva Pharma, the world’s largest generics company, acquired Barr Pharma, the US’ fourth largest generics firm. There are two questions on pharma analysts’ lips these days: Who’s next? Are Indian generics players targets for pharma MNCs?

Risen: By 38.6 per cent, direct tax collections during the first quarter of 2008-09, to Rs 57,373 crore, compared to 28 per cent and Rs 41,391 crore for the corresponding period last year.

A healthy dose of pharma stocks in your portfolio can be a good defensive strategy in this volatile market.

By selling out to Daiichi Sankyo, the CEO& MD of Ranbaxy hasn’t just netted a Rs 9,576-crore windfall, but brightened the company's future sans him in the global generics' marketplace. A report by Business Today's Shalini S. Dagar. Ranbaxy will continue acquisition, says CEORanbaxy to sell stake to Japan's Daiichi

As our cover package points out, the massive subsidies being doled out by the government to shield consumers from high oil prices may actually be compromising the country's long-term ability to sustain high growth rates and also oil conservation efforts.

A year ago in late May 2007, Mumbai-headquartered Sun Pharma, together with its subsidiaries, had signed 'definitive agreements' to acquire Taro Pharmaceutical Industries, a multinational manufacturer of generic pharmaceuticals. A year later, the transaction is in tatters and both parties are washing dirty linen in public. Why? T.V. Mahalingam finds out the reasons.

The market is going through a rough phase as it navigates cross-currents. What should investors do?

The sheer amount of manufacturing activity taking place in small towns of India is mindboggling. Shops are being set up at breakneck speed and there is massive expansion. Where are these clusters located, and can they really deliver on their promise? Here is what Business Today discovered.

Dr Reddy’s makes three niche acquisitions in 30 days.

Over the past 3-4 years, a number of domestic firms have bid for South African companies. Why is India Inc. headed to South Africa?

High compensation awaits clinical research professionals.

It has been a good recovery for the stock markets so far. Whether stock markets rise or fall, smart money will always chase sound stocks. Here’s what you should keep an eye on.

India Inc is waking up to nanotechnology, and this promises to change the way you live—whether by arresting the biological ageing process or curing diseases, such as cancer, diabetes and HIV-AIDS, or even bringing out the best from shampoos and airconditioners. A report by Nitya Varadarajan.